NCT03831984 is a Phase 4 clinical trial of 0,09% Bromfenac in Cataract, sponsored by Hospital de La Luz.

Who is sponsoring NCT03831984?

NCT03831984 is sponsored by Hospital de La Luz.

What drugs are being tested in NCT03831984?

Interventions in NCT03831984: 0,09% Bromfenac, 0,1% sodium hyaluronate.

Is NCT03831984 still recruiting?

NCT03831984 is currently status unknown. Last updated 6 February 2019.

Last reviewed 2019-02-06 · How we verify

NCT03831984

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Bromfenac for Intraoperative Miosis and Pain Reduction

Status unknown Phase 4 Last updated 6 February 2019

What this trial tests

Phase 4 trial testing 0,09% Bromfenac in Cataract in 60 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
30 November 2018

30 March 2019

Quick facts

Lead sponsor	Hospital de La Luz
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	1 March 2018
Primary completion	30 November 2018
Estimated completion	30 March 2019
Sites	1 location across Mexico

Drugs / interventions tested

0,09% Bromfenac — full drug profile →
0,1% sodium hyaluronate — full drug profile →

Conditions studied

Cataract — all drugs for Cataract →

Sponsor

Hospital de La Luz

Who can join

18 and older, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the effect of bromfenac ophthalmic solution 0.09% for reduction of intraoperative miosis and pain in patient who have undergone femtosecond laser-assisted cataract surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacologic interventions for mydriasis in cataract surgery.
Iftikhar M, Abariga SA, Hawkins BS, Zafar S, et al · · 2021 · cited 3× · PMID 34043237 · DOI 10.1002/14651858.cd012830.pub2

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting

Other Hospital de La Luz trials

Trials by the same sponsor.

NCT04204954 — Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03831984 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital de La Luz
Last refreshed: 6 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03831984.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing